ArticleThe Lancet. Oncology2022
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
Pierpaolo Correale et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
ArticleThe Lancet. Oncology2022
Pierpaolo Correale et al.PubMed ↗Publisher ↗
No numbers read from the abstract.